Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Galapagos NV | 119 |
| 2 | AbbVie Inc | 106 |
| 3 | Chiesi Farmaceutici SpA | 89 |
| 4 | Gilead Sciences Inc | 84 |
| 5 | Merck Sharp & Dohme LLC | 76 |
| 6 | Intellikine LLC | 56 |
| 7 | Glaxo Group Ltd | 49 |
| 8 | Amira Pharmaceuticals Inc | 46 |
| 9 | Aquestive Therapeutics Inc | 46 |
| 10 | Merck Canada Inc | 46 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 2,758 |
| 2 | A61K | Medicinal preparations | 2,585 |
| 3 | C07D | Heterocyclic compounds | 1,359 |
| 4 | C07K | Peptides | 690 |
| 5 | A61M | Devices for introducing media into the body | 457 |
| 6 | Y02A | Climate change adaptation | 425 |
| 7 | G01N | Investigating / analysing materials | 285 |
| 8 | C07F | Organometallic compounds | 212 |
| 9 | C07B | General methods of organic chemistry | 173 |
| 10 | C12N | Microorganisms, enzymes | 153 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Asthma and respiratory diseases | 9 |
| 2 | Chronic Obstructive Pulmonary Disease (COPD) Research | 5 |
| 3 | Inhalation and Respiratory Drug Delivery | 2 |
| 4 | Medical Research and Treatments | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Amanda Emmett | Research Triangle Park Foundation | 12 |
| 2 | Anand A. Dalal | Research Triangle Park Foundation | 11 |
| 3 | Dave Singh | University of Manchester | 11 |
| 4 | Donald Banerji | Novartis (United States) | 11 |
| 5 | Claus Vogelmeier | Philipps University of Marburg | 10 |
| 6 | Francesco Patalano | Novartis (Switzerland) | 9 |
| 7 | Jadwiga A. Wedzicha | Imperial College London | 8 |
| 8 | Brian J. Lipworth | Ninewells Hospital | 7 |
| 9 | David A. Stempel | Research Triangle Park Foundation | 7 |
| 10 | David Price | University of Aberdeen | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial | 2016 | 884 | Asthma and respiratory diseases |
| Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD | 2016 | 877 | Asthma and respiratory diseases |
| Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease | 2002 | 508 | Asthma and respiratory diseases |
| Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD | 2015 | 327 | Asthma and respiratory diseases |
| Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study | 2012 | 315 | Asthma and respiratory diseases |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and weight of Adoair?
What are the main patent assignees associated with Adoair-related innovations?
Which research areas dominate the scientific literature on Adoair?
What are the most-cited published studies on Adoair or closely related compounds?
How has patenting activity in the Adoair field trended in recent years?